{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:42:59Z","timestamp":1793241779779,"version":"4.5.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000650","name":"Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000650","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.esmoop.2024.104122","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T14:31:14Z","timestamp":1737988274000},"page":"104122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Is pathological response an adequate surrogate marker for survival in neoadjuvant therapy with immune checkpoint inhibitors?"],"prefix":"10.1016","volume":"10","author":[{"given":"K.","family":"Sugiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Okines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.esmoop.2024.104122_bib1","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.esmoop.2024.104122_bib2","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O\u2019Brien","year":"2022","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.esmoop.2024.104122_bib3","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.esmoop.2024.104122_bib4","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"10308","key":"10.1016\/j.esmoop.2024.104122_bib5","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.esmoop.2024.104122_bib6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2024.104122_bib7","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.esmoop.2024.104122_bib8","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.104122_bib98","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"14","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.esmoop.2024.104122_bib9","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2024.104122_bib10","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/2159-8290.CD-21-1141","article-title":"Adjuvant pembrolizumab versus IFN\u03b12b or ipilimumab in resected high-risk melanoma","volume":"12","author":"Grossmann","year":"2022","journal-title":"Cancer Discov"},{"issue":"10336","key":"10.1016\/j.esmoop.2024.104122_bib11","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.esmoop.2024.104122_bib12","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","article-title":"Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial","volume":"29","author":"Kirkwood","year":"2023","journal-title":"Nat Med"},{"issue":"19","key":"10.1016\/j.esmoop.2024.104122_bib13","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6477","key":"10.1016\/j.esmoop.2024.104122_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.esmoop.2024.104122_bib15","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.1158\/1078-0432.CCR-18-2641","article-title":"The promise of neoadjuvant immunotherapy and surgery for cancer treatment","volume":"25","author":"O\u2019Donnell","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2024.104122_bib16","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"9938","key":"10.1016\/j.esmoop.2024.104122_bib17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.esmoop.2024.104122_bib18","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2024.104122_bib19","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2007.13.9550","volume":"26","author":"Dooms","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.104122_bib20","article-title":"Association of pathologic complete response and long-term survival outcomes among patients treated with neoadjuvant chemotherapy or chemoradiotherapy for NSCLC: a meta-analysis","volume":"3","author":"Rosner","year":"2022","journal-title":"JTO Clin Res Rep"},{"issue":"2","key":"10.1016\/j.esmoop.2024.104122_bib21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.104122_bib22","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S1470-2045(10)70172-8","article-title":"Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data","volume":"11","author":"Maas","year":"2010","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.104122_bib23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"28","key":"10.1016\/j.esmoop.2024.104122_bib24","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.104122_bib25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","article-title":"IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy","volume":"15","author":"Travis","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2024.104122_bib26","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2024.104122_bib27","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C","article-title":"Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations","volume":"73","author":"Mandard","year":"1994","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2024.104122_bib28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/cncr.23136","article-title":"Prognostic significance of mesenteric tumor nodules in patients with stage III colorectal cancer","volume":"112","author":"Lo","year":"2008","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2024.104122_bib29","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1097\/PAS.0000000000001371","article-title":"Multicenter validation of histopathologic tumor regression grade after neoadjuvant chemotherapy in muscle-invasive bladder carcinoma","volume":"43","author":"Voskuilen","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"22","key":"10.1016\/j.esmoop.2024.104122_bib30","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","article-title":"Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma","volume":"33","author":"B\u00f6hm","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.104122_bib31","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","article-title":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","volume":"29","author":"Tetzlaff","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.104122_bib32","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1158\/1078-0432.CCR-19-2379","article-title":"Pan-tumor pathologic scoring of response to PD-(L)1 blockade","volume":"26","author":"Stein","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2024.104122_bib33","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","article-title":"Association between pathologic response and survival after neoadjuvant therapy in lung cancer","volume":"30","author":"Deutsch","year":"2024","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.esmoop.2024.104122_bib81","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1378\/chest.120.5.1584","article-title":"Grading of tumor regression in non-small cell lung cancer: morphology and prognosis","volume":"120","author":"Junker","year":"2001","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.esmoop.2024.104122_bib82","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/JTO.0b013e318247504a","article-title":"Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy","volume":"7","author":"Pataer","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.104122_bib34","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/oncolo\/oyac006","article-title":"Surrogacy beyond prognosis: the importance of \u2018trial-level\u2019 surrogacy","volume":"27","author":"Buyse","year":"2022","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.esmoop.2024.104122_bib35","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz002","article-title":"A\u00a0systematic review and recommendation for reporting of surrogate endpoint evaluation using meta-analyses","volume":"3","author":"Xie","year":"2019","journal-title":"JNCI Cancer Spectr"},{"issue":"1","key":"10.1016\/j.esmoop.2024.104122_bib36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/biostatistics\/1.1.49","article-title":"The validation of surrogate endpoints in meta-analyses of randomized experiments","volume":"1","author":"Buyse","year":"2000","journal-title":"Biostatistics"},{"issue":"34","key":"10.1016\/j.esmoop.2024.104122_bib37","doi-asserted-by":"crossref","first-page":"8664","DOI":"10.1200\/JCO.2005.01.6071","article-title":"Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials","volume":"23","author":"Sargent","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"29","key":"10.1016\/j.esmoop.2024.104122_bib38","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1200\/JCO.2006.10.4323","article-title":"End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group","volume":"25","author":"Sargent","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2024.104122_bib39","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1001\/jamaoncol.2022.3755","article-title":"Surrogacy of pathologic complete response in trials of neoadjuvant therapy for early breast cancer: critical analysis of strengths, weaknesses, and misinterpretations","volume":"8","author":"Conforti","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2024.104122_bib40","article-title":"Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis","volume":"375","author":"Conforti","year":"2021","journal-title":"BMJ"},{"issue":"21","key":"10.1016\/j.esmoop.2024.104122_bib43","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2024.104122_bib44","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1158\/1078-0432.CCR-22-2994","article-title":"Five-year clinical outcomes after neoadjuvant nivolumab in resectable non-small cell lung cancer","volume":"29","author":"Rosner","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.esmoop.2024.104122_bib47","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: The neotorch randomized clinical trial","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.esmoop.2024.104122_bib49","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.esmoop.2024.104122_bib50","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2024.104122_bib51","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.annonc.2024.02.002","article-title":"Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522","volume":"35","author":"Pusztai","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.104122_bib52","doi-asserted-by":"crossref","first-page":"S1260","DOI":"10.1016\/j.annonc.2023.10.011","article-title":"LBA21 KEYNOTE-756: phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo)\u00a0+ chemotherapy (chemo), followed by adjuvant pembro or pbo\u00a0+ endocrine therapy (ET) for early-stage high-risk ER+\/HER2\u2212 breast cancer","volume":"34","author":"Cardoso","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.104122_bib53","doi-asserted-by":"crossref","first-page":"S1259","DOI":"10.1016\/j.annonc.2023.10.010","article-title":"LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) \u00b1 NIVO in patients (pts) with high-risk, ER+ HER2\u2212 primary breast cancer (BC)","volume":"34","author":"Loi","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.104122_bib62","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial","volume":"28","author":"Reijers","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.esmoop.2024.104122_bib60","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.104122_bib61","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.annonc.2023.01.004","article-title":"Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials","volume":"34","author":"Versluis","year":"2023","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.104122_bib63","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.esmoop.2024.104122_bib65","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2024.104122_bib73","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.104122_bib75","article-title":"LBA3 Final analysis of the phase III KEYNOTE-585 study of pembrolizumab plus chemotherapy vs chemotherapy as perioperative therapy in locally-advanced gastric and gastroesophageal junction cancer","volume":"35","author":"Shitara","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.104122_bib78","doi-asserted-by":"crossref","first-page":"S1315","DOI":"10.1016\/j.annonc.2023.10.074","article-title":"LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC\/GEJC): interim results of the global, phase III MATTERHORN study","volume":"34","author":"Janjigian","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.104122_bib79","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.esmoop.2024.104122_bib41","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1056\/NEJMoa043623","article-title":"Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer","volume":"352","author":"Winton","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.esmoop.2024.104122_bib42","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1200\/JCO.19.02674","article-title":"Randomized phase III study of pemetrexed plus cisplatin versus vinorelbine plus cisplatin for completely resected stage II to IIIA nonsquamous non-small-cell lung cancer","volume":"38","author":"Kenmotsu","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.104122_bib45","doi-asserted-by":"crossref","first-page":"S1297","DOI":"10.1016\/j.annonc.2023.10.052","article-title":"LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)","volume":"34","author":"Spicer","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.104122_bib46","doi-asserted-by":"crossref","first-page":"S1299","DOI":"10.1016\/j.annonc.2023.10.054","article-title":"LBA58 Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIA NSCLC patients (pts) in the phase III (Ph3) RATIONALE-315 trial","volume":"34","author":"Yue","year":"2023","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2024.104122_bib48","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.104122_bib99","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.jtho.2024.03.010","article-title":"Evaluation of major pathologic response and pathologic complete response as surrogate end points for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable in NSCLCJ","volume":"19","author":"Hines","year":"2024","journal-title":"Thorac Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2024.104122_bib54","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2024.104122_bib55","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1200\/JCO.19.01381","article-title":"Phase III study of adjuvant ipilimumab (3 or 10 mg\/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma: North American intergroup E1609","volume":"38","author":"Tarhini","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.104122_bib56","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.104122_bib57","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.104122_bib58","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A\u00a0single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.esmoop.2024.104122_bib59","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2024.104122_bib64","doi-asserted-by":"crossref","first-page":"S1288","DOI":"10.1016\/j.annonc.2023.10.042","article-title":"LBA48 Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb-IV melanoma from SWOG S1801","volume":"34","author":"Patel","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.104122_bib97","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)","volume":"27","author":"Menzies","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.esmoop.2024.104122_bib66","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.esmoop.2024.104122_bib67","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2024.104122_bib68","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.104122_bib69","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1245\/s10434-018-07147-0","article-title":"The prognostic value of a pathologic complete response after neoadjuvant therapy for digestive cancer: systematic review and meta-analysis of 21 studies","volume":"26","author":"Wan","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.104122_bib70","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1093\/annonc\/mdt141","article-title":"Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy","volume":"24","author":"Lorenzen","year":"2013","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2024.104122_bib71","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1200\/JCO.2015.65.7692","article-title":"Effect of pathologic tumor response and nodal status on survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy trial","volume":"34","author":"Smyth","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2024.104122_bib72","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1038\/s41416-023-02217-x","article-title":"Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials","volume":"128","author":"Athauda","year":"2023","journal-title":"Br J Cancer"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2024.104122_bib74","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JCO.2024.42.3_suppl.247","article-title":"Pembrolizumab plus FLOT vs FLOT as neoadjuvant and adjuvant therapy in locally advanced gastric and gastroesophageal junction cancer: interim analysis of the phase 3 KEYNOTE-585 study","volume":"42","author":"Al-Batran","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2024.104122_bib76","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.2024.42.16_suppl.4073","article-title":"Neoadjuvant\/adjuvant pembrolizumab (pembro)\u00a0+ chemotherapy (chemo) vs placebo (pbo)\u00a0+ chemo for gastric\/gastroesophageal junction (G\/GEJ) adenocarcinoma: major pathologic response (mPR) in KEYNOTE-585","volume":"42","author":"Shitara","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2024.104122_bib77","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.2217\/fon-2022-0093","article-title":"MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric\/gastroesophageal junction cancer","volume":"18","author":"Janjigian","year":"2022","journal-title":"Future Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2024.104122_bib80","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N\u00a0Engl J Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924018933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924018933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:46:50Z","timestamp":1740124010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924018933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2059702924018933"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.104122","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is pathological response an adequate surrogate marker for survival in neoadjuvant therapy with immune checkpoint inhibitors?","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.104122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"104122"}}